These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors. van der Bijl P, van der Bijl P. Int J Immunopathol Pharmacol; 2003 Dec; 16(2 Suppl):17-22. PubMed ID: 14552700 [Abstract] [Full Text] [Related]
9. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM. Nature; 1995 Nov 23; 378(6555):406-9. PubMed ID: 7477380 [Abstract] [Full Text] [Related]
10. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? Hersh EV, Lally ET, Moore PA. Curr Med Res Opin; 2005 Aug 23; 21(8):1217-26. PubMed ID: 16083531 [Abstract] [Full Text] [Related]
11. New directions in cyclooxygenase research and their implications for NSAID-gastropathy. Flower RJ. Ital J Gastroenterol; 1996 Dec 23; 28 Suppl 4():23-7. PubMed ID: 9032578 [Abstract] [Full Text] [Related]
12. Dual acting anti-inflammatory drugs: a reappraisal. Bertolini A, Ottani A, Sandrini M. Pharmacol Res; 2001 Dec 23; 44(6):437-50. PubMed ID: 11735348 [Abstract] [Full Text] [Related]
18. [Is there a future for COX-2 inhibitors?]. Yodfat Y. Harefuah; 2004 Nov 23; 143(11):820-4, 837. PubMed ID: 15603272 [Abstract] [Full Text] [Related]